-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100

Benzinga·10/30/2026 18:31:07
Listen to the news
TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $110 to $100.